SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MDC, HARP, CVLY, AXNX
January 24, 2024 17:17 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
ALERT: The M&A Class Action Firm Continues Investigating the Merger – GRCL, AXNX, HARP, CVLY
January 19, 2024 20:00 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Kuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law Firm
January 19, 2024 13:15 ET
|
KUEHN LAW, PLLC
Kuehn Law investigates HA, ICVX, PXD, HARP mergers, seeks to protect shareholder interests. Shareholders urged to contact the firm.
STOCKHOLDER ALERT: Juan Monteverde Encourages the Shareholders of HARP, VIA, RYZB, FGH to Take Action
January 09, 2024 17:36 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 16:30 ET
|
Harpoon Therapeutics
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical...
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
April 18, 2023 13:30 ET
|
Harpoon Therapeutics
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor...
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
April 17, 2023 13:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented...
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
April 10, 2023 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023 16:05 ET
|
Harpoon Therapeutics
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million...
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
March 27, 2023 16:02 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers,...